Genmab — November 2015
-
går=år
-
EM1 duo fra JJ firmly slotted for 2015 clinic
-
will dose first patient 2015
-
tiers har ikke carry back
-
men 20% er ikke ved et særligt højt sales no. men David må ikke sige hvor meget
-
ca 15% ved usd 3 mia i salg
-
"will not embarrass me too much" siger David
-
men er det ikke ved et højere salg - passer vel meget godt med salg på 5 mia
-
ASH will be HOT
-
cost savings mostly fordi materialer til axl og tf først bliver leveret i 2016 - så mere periodisering end noget andet
-
lyder til at R&D update på post ash bliver ret omfattende
-
mon ikke!!!
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind